This suggests that KRAS mutated AAH may not progress to adenocarcinoma in the same way proposed for EGFR mutated AAH [23-25], and that KRAS mutations occur in adenocarcinoma de novo via an alternative pathogenesis [26]. The gene discussed is EGFR; the disease is adenocarcinoma.